These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 33634757)

  • 1. PROTACs in Treatment of Cancer: A Review.
    Arora P; Singh M; Singh V; Bhatia S; Arora S
    Mini Rev Med Chem; 2021; 21(16):2347-2360. PubMed ID: 33634757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
    Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
    Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
    Reboud-Ravaux M
    Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future.
    Li R; Liu M; Yang Z; Li J; Gao Y; Tan R
    Molecules; 2022 Dec; 27(24):. PubMed ID: 36557960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Advances in Small Molecule PROTACs for the Treatment of Cancer.
    Li W; Elhassan RM; Hou X; Fang H
    Curr Med Chem; 2021; 28(24):4893-4909. PubMed ID: 33208057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-molecule PROTACs: novel agents for cancer therapy.
    Wan Y; Yan C; Gao H; Liu T
    Future Med Chem; 2020 May; 12(10):915-938. PubMed ID: 32270707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Developments in Medicinal Chemistry and Therapeutic Potential of Anti-Cancer PROTACs-Based Molecules.
    Irshad Khan MZ; Nazli A; Pan YL; Chen JZ
    Curr Med Chem; 2023; 30(14):1576-1622. PubMed ID: 35927805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PROTAC-DB 2.0: an updated database of PROTACs.
    Weng G; Cai X; Cao D; Du H; Shen C; Deng Y; He Q; Yang B; Li D; Hou T
    Nucleic Acids Res; 2023 Jan; 51(D1):D1367-D1372. PubMed ID: 36300631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs.
    An S; Fu L
    EBioMedicine; 2018 Oct; 36():553-562. PubMed ID: 30224312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted protein degradation by PROTACs.
    Neklesa TK; Winkler JD; Crews CM
    Pharmacol Ther; 2017 Jun; 174():138-144. PubMed ID: 28223226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PROTACs: Promising approach for anticancer therapy.
    Kaur SD; Bedi N; Kumar D; Kapoor DN
    Cancer Lett; 2023 Mar; 556():216065. PubMed ID: 36642326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stimuli-activatable PROTACs for precise protein degradation and cancer therapy.
    Gao J; Yang L; Lei S; Zhou F; Nie H; Peng B; Xu T; Chen X; Yang X; Sheng C; Rao Y; Pu K; Jin J; Xu Z; Yu H
    Sci Bull (Beijing); 2023 May; 68(10):1069-1085. PubMed ID: 37169612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
    Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
    Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PROTACs as Potential Therapeutic Agents for Cancer Drug Resistance.
    Sun X; Rao Y
    Biochemistry; 2020 Jan; 59(3):240-249. PubMed ID: 31661257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PROTAC-DB: an online database of PROTACs.
    Weng G; Shen C; Cao D; Gao J; Dong X; He Q; Yang B; Li D; Wu J; Hou T
    Nucleic Acids Res; 2021 Jan; 49(D1):D1381-D1387. PubMed ID: 33010159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New-generation advanced PROTACs as potential therapeutic agents in cancer therapy.
    Wang C; Zhang Y; Chen W; Wu Y; Xing D
    Mol Cancer; 2024 May; 23(1):110. PubMed ID: 38773495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PROTACs: great opportunities for academia and industry (an update from 2020 to 2021).
    He M; Cao C; Ni Z; Liu Y; Song P; Hao S; He Y; Sun X; Rao Y
    Signal Transduct Target Ther; 2022 Jun; 7(1):181. PubMed ID: 35680848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteolysis targeting chimeras (PROTACs) for epigenetics research.
    Vogelmann A; Robaa D; Sippl W; Jung M
    Curr Opin Chem Biol; 2020 Aug; 57():8-16. PubMed ID: 32146413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy.
    Li X; Song Y
    J Hematol Oncol; 2020 May; 13(1):50. PubMed ID: 32404196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
    He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
    J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.